Catalent completes $4.6 million expansion at Singapore clinical supply facility

28 Feb 2018

Expansion supports multinational customers’ growing needs for full clinical supply services and provides flexible solutions for local customers in the Asia-Pacific region.

Catalent Pharma Solutions has completed a 2-year, $4.6 million expansion at its Singapore clinical supply facility. The company made the announcement at the PHAR-EAST Pharma and Biotech Festival, which is currently taking place at the Suntec Singapore Convention & Exhibition Centre.

Catalent completes $4.6 million expansion at Singapore clinical supply facility

The facility is a key strategic hub in Catalent’s Asia-Pacific network and global clinical supply business, supporting multinational customers’ growing needs for full clinical supply services, while providing flexible solutions for local customers in the Asia-Pacific region. The new expansion provides additional GMP space for secondary packaging, has doubled ambient storage, and quadrupled cold storage capacity at the site.

The site has seen significant growth since opening in 1998, almost tripling in size and now standing at almost 20,000-sq ft, with headcount also tripling since 2012.

“We are particularly pleased to have completed the expansion in a year that marks the 20th anniversary of what was Catalent’s first facility in the Asia-Pacific region,” commented Bernie Clark, VP Marketing, Catalent Clinical Supply Services. He added: “Supported by many long-serving employees, the Singapore site has undergone tremendous growth over the past two decades and now routinely distributes to 18 countries in the region.”

Read More

Related tags

Market News

Related news

BIA Separations expands with new upstream processing facility

BIA Separations expands with new upstream processing facility

20 Sep 2018

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Recipharm connects to European Hub for serialisation compliance

Recipharm connects to European Hub for serialisation compliance

18 Sep 2018

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

Read more 
Bosch to unveil new laboratory device for continuous manufacturing

Bosch to unveil new laboratory device for continuous manufacturing

18 Sep 2018

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Read more 
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

17 Sep 2018

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Read more 
Cambrex expands manufacturing footprint with acquisition

Cambrex expands manufacturing footprint with acquisition

16 Sep 2018

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Read more 
NMPA approves fruquintinib capsules for metastatic colorectal cancer

NMPA approves fruquintinib capsules for metastatic colorectal cancer

13 Sep 2018

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

Read more 
Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more